|
Sign In to gain access to subscriptions and/or personal tools.
|
Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy
Z Blumenfeld
Reproductive Endocrinology and Introduction Infertility Section, Department of Obstetrics and Gynecology, Technion Faculty of Medicine, Rambam Medical Center, Haifa Premature ovarian failure (POF) is a common long-31096, Israel. Tel: (+ 972) 4 8542577; Fax: (+ 972) 4 8542612, (+ 972)4 851 5710; bzeevtechunix.technion.ac.il
D Shapiro
Rheumatology, Rambam Medical Center, Technion Faculty of Medicine, Israel Institute of Technology, Haifa, Israel
M Shteinberg
Reproductive Endocrinology, Departments of Obstetrics and Gynecology, Rambam Medical Center, Technion Faculty of Medicine, Israel Institute of Technology, Haifa, Israel
I Avivi
Hematology, Rambam Medical Center, Technion Faculty of Medicine, Israel Institute of Technology, Haifa, Israel
M Nahir
Rheumatology, Rambam Medical Center, Technion Faculty of Medicine, Israel Institute of Technology, Haifa, Israel
Background: Premature ovarian failure (POF) is a common long-term consequence of chemotherapy. Whereas the cytotoxic-induced damage is reversible in other tissues of rapidly dividing cells such as bone marrow, gastrointestinal tract and thymus, it appears to be progressive and irreversible in the ovary, where the number of germ cells is limited, fixed since the fetal life, and cannot be regenerated. The gonadal toxicity of cyclophosphamide is well known. In patients with lupus nephritis, premature ovarian failure (POF) was reported in half of all treated women after cyclophosphamide pulse therapy, affecting 100% of those older than 30y, about 50% of the patients between the ages of 20-30y and only 13% of the patients younger than 20y of age. Following our preliminary encouraging experience in women with lymphoma, whereby the temporary induction of a prepubertal hormonal milieu, during chemotherapy, has significantly decreased the risk of POF, we have administered a monthly injection of gonadotropin-releasing hormone agonistic analogue (GnRH-a) to eight young women in parallel to alkylating agent chemotherapy.
Materials and methods: A monthly intramuscular depot injection of 3.75 mg D-TRP6-GnRH-a (Decapeptyl C.R.) was administered after informed consent to eight women with autoimmune, severe connective tissue diseases (seven SLE patients and one woman with nephrotic syndrome) in parallel to chemotherapy, for up to six months. The institutional committee for human experimentation approved the protocol. The concentrations of FSH, LH, progesterone, and 17-/3-estradiol (E2) were measured before, during and after the GnRH-a/chemotherapy treatment. A transvaginal (or transabdominal) sonography (TVS) was performed on each patient before and after treatment. These eight treated patients (study group) were compared to a group of nine women similarly treated by cyclophosphamide pulses (CPT) or chlorambucil for SLE/connective tissue disease but were not referred for the GnRH-a adjuvant treatment.
Results: Whereas none of the eight women receiving GnRH-a in parallel to alkylating agent chemotherapy (cyclophosphamide (7) or chlorambucil (1)) suffered POF and hypergonadotropic amenorrhea, five of the nine (> 50%) patients treated by alkylating agents (cyclophosphamide (8) or chlorambucil (I)) experienced POF. Whereas two of these five women were 35 y old, the other three were < 23 y old at the time of the chemotherapeutic insult.
Conclusions: Our present results, extrapolating this encouraging experience from hematological malignant diseases to severe connective tissue diseases, such as SLE associated nephropathy or others, suggests that the beneficial effect of GnRH-a co-treatment may be exploited towards preservation of future fertility and ovarian function in every young woman of reproductive age, exposed to alkylating agents, such as cyclophosphamide and chlorambucil.
Key Words: SLE • chemotherapy • gonadotoxicity • POF • fertility • cytotoxicity
Lupus, Vol. 9, No. 6,
401-405 (2000)
DOI: 10.1191/096120300678828596
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Beck-Fruchter, A. Weiss, and E. Shalev
GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data
Hum. Reprod. Update,
November 1, 2008;
14(6):
553 - 561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Houssiau and E. Ginzler
Current treatment of lupus nephritis
Lupus,
May 1, 2008;
17(5):
426 - 430.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Sinha and J. M Dionne
SHOULD GONADOTROPIN RELEASING HORMONE ANALOGUE BE ADMINISTERED TO PREVENT PREMATURE OVARIAN FAILURE IN YOUNG WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS ON CYCLOPHOSPHAMIDE THERAPY?
Arch. Dis. Child.,
May 1, 2008;
93(5):
444 - 445.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Blumenfeld
How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries
Oncologist,
September 1, 2007;
12(9):
1044 - 1054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Oktay, M. Sonmezer, O. Oktem, K. Fox, G. Emons, and H. Bang
Absence of Conclusive Evidence for the Safety and Efficacy of Gonadotropin-Releasing Hormone Analogue Treatment in Protecting Against Chemotherapy-Induced Gonadal Injury
Oncologist,
September 1, 2007;
12(9):
1055 - 1066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.A.A. Silva and H.I. Brunner
Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus
Lupus,
August 1, 2007;
16(8):
593 - 599.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tincani, M. Nuzzo, A. Lojacono, M. Cattalini, and A. Meini
Review: Contraception in adolescents with systemic lupus erythematosus
Lupus,
August 1, 2007;
16(8):
600 - 605.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Donnez, B. Martinez-Madrid, P. Jadoul, A. Van Langendonckt, D. Demylle, and M.-M. Dolmans
Ovarian tissue cryopreservation and transplantation: a review
Hum. Reprod. Update,
September 1, 2006;
12(5):
519 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Goswami and G. S. Conway
Premature ovarian failure
Hum. Reprod. Update,
July 1, 2005;
11(4):
391 - 410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Blumenfeld and A. Eckman
Preservation of Fertility and Ovarian Function and Minimization of Chemotherapy-Induced Gonadotoxicity in Young Women by GnRH-a
J Natl Cancer Inst Monographs,
March 1, 2005;
2005(34):
40 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gorman, A. Bhatia, and A. Rahman
This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis
Rheumatology,
March 1, 2005;
44(3):
398 - 401.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F A Houssiau
Cyclophosphamide in lupus nephritis
Lupus,
January 1, 2005;
14(1):
53 - 58.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas
Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus
Lupus,
December 1, 2004;
13(12):
887 - 890.
[PDF]
|
|
|
|
|
|
|
M-C Park, Y-B Park, S Y Jung, I H Chung, K H Choi, and S-K Lee
Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy
Lupus,
August 1, 2004;
13(8):
569 - 574.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Sonmezer and K. Oktay
Fertility preservation in female patients
Hum. Reprod. Update,
May 1, 2004;
10(3):
251 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Letterie
Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure
Hum. Reprod.,
April 1, 2004;
19(4):
831 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Milne, K. P. Stanley, R. C. Temple, T. H. Barker, and C. N. Ross
Microscopic polyangiitis: first report of a case with onset during pregnancy
Nephrol. Dial. Transplant.,
January 1, 2004;
19(1):
234 - 237.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Revel and J. Schenker
Ovarian tissue banking for cancer patients: is ovarian cortex cryopreservation presently justified?
Hum. Reprod.,
January 1, 2004;
19(1):
14 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Petri
Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy
Lupus,
March 1, 2001;
10(3):
222 - 226.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Petri
The egg and I: preserving fertility in systemic lupus erythematosus
Lupus,
July 1, 2000;
9(6):
399 - 400.
[PDF]
|
|
|
|
|
